Thursday, March 16, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

Liposomal Ciprofloxacin as Broad-Spectrum Bioterrorism Countermeasures

by Global Biodefense Staff
October 20, 2016
laboratory tubes and droppers

The U.K. Defence Science and Technology Laboratory (Dstl) has received funding of up to $6.9 million from the U.S. Defense Threat Reduction Agency (DTRA) for a program entitled “Inhalational ciprofloxacin for improved protection against biowarfare agents”.

The inhalational ciprofloxacin formulations used in this program are Aradigm’s proprietary investigational drugs Pulmaquin and Lipoquin.

Dstl, with key sub-contractors including Aradigm Corporation, will conduct research relating to the efficacy of the two drugs in animal models of the following agents:

  • Francisella tularensis (tularemia)
  • Burkholderia pseudomallei (melioidosis)
  • Burkholderia mallei (glanders)
  • Coxiella burnetii (Q-fever)

The most likely method for infection with biowarfare agents is via the pulmonary route. The main advantage of the inhaled liposomal ciprofloxacin approach is that it delivers the antibiotic rapidly and directly in high concentrations to the respiratory tract – the area of primary infection – and the liposomal formulation retains it there over a prolonged period of time.

The liposomal formulation also facilitates intracellular uptake, essential to treat these life-threatening intracellular infections.

“We have been very pleased with the earlier compelling efficacy findings with Pulmaquin and Lipoquin in rodent models of inhalational tularemia, plague and Q-fever. We have also accumulated a substantial amount of animal and human safety data to date,” said James Blanchard, Aradigm’s Principal Scientist. “The funding from DTRA will enable us to validate and expand this approach with the goal of providing broad-spectrum prophylaxis and treatment against multiple bioterrorism threats.”

The total potential funding provided to Dstl is $3.2M for the base period and $3.7M for the option period. The initial funding released is $1.7M.

Tags: BioterrorismBurkholderiaF. tularensisQ Fever

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy